Advanced search
Publication Cover
Expert Review of Anticancer Therapy Latest Articles
Submit an article Journal homepage
193
Views
0
CrossRef citations to date
0
Altmetric
Editorial

The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer

Gianluca Ingrossoa Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4380-6947View further author information
ORCID Icon,
Andrea Lanciab Department of Radiation Oncology, Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, ItalyORCID Iconhttps://orcid.org/0000-0001-6106-7725View further author information
ORCID Icon,
Eleonora Festaa Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, ItalyView further author information
,
Antonio Rosario Pisanic Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, ItalyORCID Iconhttps://orcid.org/0000-0002-3335-9541View further author information
ORCID Icon,
Rita Bellavitaa Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, ItalyView further author information
,
Cynthia Aristeia Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital, Perugia, ItalyView further author information
&
Beatrice Dettid Radiation Oncology Department, USL Centro Toscana - Prato, Prato, ItalyView further author information
 show all
Received 04 Apr 2024, Accepted 26 Apr 2024, Published online: 02 May 2024

References

  • Bukavina L, Bensalah K, Bray F, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82(5):529–542. doi: 10.1016/j.eururo.2022.08.019
  • European Cancer Information System. 2024 Mar 15. Available from https://ecis.jrc.ec.europa.eu/
  • Lancia A, Ingrosso G, Carosi A, et al. Oligometastatic cancer in elderly patients: the “blitzkrieg” radiotherapy approach: SBRT in oligometastatic elderly patients. Aging Clin Exp Res. 2019;31(1):109–114. doi: 10.1007/s40520-018-0937-6
  • Siva S, Ali M, Correa RJM, et al. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the international radiosurgery consortium of the kidney). Lancet Oncol. 2022;23(12):1508–1516. doi: 10.1016/S1470-2045(22)00656-8
  • Zaorsky NG, Lehrer EJ, Kothari G, et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019;2(5):515–523. doi: 10.1016/j.euo.2019.05.007
  • Siva S, Bressel M, Sidhom M, et al. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol. 2024;25(3):308–316. doi: 10.1016/S1470-2045(24)00020-2
  • Hannan R, Kim SE, Cole S, et al. Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR). J Clin Oncol. 2024;42(4_suppl):TPS489–TPS489. doi: 10.1200/JCO.2024.42.4_suppl.TPS489
  • De Meerleer G, Khoo V, Escudier B, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170–7. doi: 10.1016/S1470-2045(13)70569-2
  • Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888–898. doi: 10.1016/S1470-2045(22)00290-X
  • Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med. 2023;388(19):1767–1778. doi: 10.1056/NEJMoa2212851
  • Guidelines on renal cell carcinoma. Eur Assoc Urol. 2024. https://uroweb.org/guidelines/renal-cell-carcinoma
  • Hannan R, McLaughlin MF, Pop LM, et al. Phase 2 trial of stereotactic ablative radiotherapy for patients with primary renal cancer. Eur Urol. 2023;84(3):275–286. doi: 10.1016/j.eururo.2023.02.016
  • Lalani AK, Swaminath A, Pond GR, et al. Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). J Clin Oncol. 2022;40(6_suppl):TPS398–TPS398. doi: 10.1200/JCO.2022.40.6_suppl.TPS398
  • Hall WA, Karrison T, McGregor BA, et al. NRG-GU012: randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI). JCO. 2023;41(S16):TPS4604–TPS4604. doi: 10.1200/JCO.2023.41.16_suppl.TPS4604
  • Ali M, Wood S, Pryor D, et al. NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): a phase II randomised clinical trial. Contemp Clin Trials Commun. 2023;33:101145. doi: 10.1016/j.conctc.2023.101145

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.